RE:New Australian Study Discusses TLD1433One of the 2 authors of this study is a
Fellow of the Royal Society of Chemistry.
That gives an even greater credibility to this paper, and to our TLD1433 molecule. So our technology cannot be ignored anymore when people of this caliber publish. This is in support to the amazing trailblazing work of Prof. McFarland.
So manke no mistake; this paper only adds to what we already know and to what clinical trial data so far is showing; clear destructive potency and efficiency against cancer cells.
See just a glimpse of her credentials:
https://www.westernsydney.edu.au/staff_profiles/WSU/professor_janice_aldrich_wright
Her work is internationally recognised in the field of anticancer chemistry and pharmacology and she has published widely. Innovative bioinorganic molecular design, elegant synthesis, comprehensive characterisation (including X-ray analysis at the synchrotron) and the biophysical analysis of the interactions of these compounds with DNA using, for example synchrotron radiation circular Dichroism (SRCD – Aarhus, Denmark), exemplify her research while creating a vibrant, productive and collaborative environment for her research students.
Brief Biography
Research
Significant contributions have been made to the investigation of metal complex-DNA interactions. Work initiated at WSU has demonstrated by 1H NMR, that both Δ- and -Λ[Ru(2,9-phenMe2)2(dpq/dppz)]2+ bind to the oligonucleotide d(GTCGAC)2 by intercalation within the minor groove. These were the first NMR experiments to do so and this finding, while controversial, is significant because the differences in binding of these simple molecules must be well understood if sequence-selective binding by metal complexes is to be realised. The work has influenced researchers to re-investigate the DNA interactions of metallointercalators with a less prejudiced view about the nature and extent of intercalation. The findings of this research were confirmed by X-ray structure analysis for more than one complex of this type in Nature Chemistry in 2012.
Ongoing research and innovative complex design at WSU has resulted in the discovery of a new class of platinum compounds that differ significantly in their mode of action from current clinically used anticancer platinum compound like chemotherapy cisplatin. Antibacterial agents that are more effective against biofilms, than currently used, have also been identified.
Other research conducted at by Janice's group at Western Sydney University has resulted in the discovery of a new group of platinum-based compounds. This new group of compounds are water-soluble and in preliminary testing against cancer cells lines and are showing a very high level of activity.
Publications
Most appear in high profile journals, with more than 3,813 citations from 119 publications (average citations per article 31.7) and an h-index 33 (Scopus: accessed, Jan 2020). ORCID ID: https://orcid.org/0000-0002-6943-6908
Professor Aldrich-Wright has supervised 27 PhD, 15 MSc and 38 Honours students to completion by establishing a dynamic research group. This group is recognised internally at Western Sydney University, and externally both nationally and internationally, as being innovative and extremely productive. All postgraduate students are encouraged to publish as much of their work as possible, before submitting their thesis for examination. In this respect, success has been demonstrated by the number of Published Patents/Book Chapters/Papers (average 4.1) and Conference Papers (average 3.3) per PhD student.
This contribution to graduate research training and supervision has been recognised by the Vice-Chancellor's Excellence Award for Postgraduate Research Training and Supervision in 2009, 2013 and 2020 and the School of Science and Health’s award for Postgraduate Research Training and Supervision 2020.
___________________________
Eoganacht - (3/2/2022 2:43:25 PM) New Australian Study Discusses TLD1433 Full text: Photoactive and Luminescent Transition Metal Complexes as Anticancer Agents: A Guiding Light in the Search for New and Improved Cancer Treatments biomedicines 2022 Received: 31 January 2022 / Revised: 23 February 2022 / Accepted: 26 February 2022 / Published: 1 March 2022
(This article belongs to the Special Issue Metal-Based Complexes in Cancer Treatment) Brondwyn S. McGhie and Janice R. Aldrich-Wright Nanoscale Organisation and Dynamics Group, School of Science, Western Sydney University "3. Ruthenium Complexes
Ruthenium complexes are a favorite when it comes to alternatives to the “traditional” platinum-based chemotherapeutics. Ruthenium complexes commonly have large Stoke shifts, high chemical, and photochemical stability; are typically highly water-soluble; and are resistant to photobleaching. In 2017, TLD1433, a ruthenium complex created by the McFarland group, became the first transition-metal-based complex to enter human clinical trials for the PDT treatment of cancer; in 2018, it succeeded in its goals in the trial and was terminated early [50].
A phase-III clinical study of TDL1433 commenced in 2019, which is expected to take 2–3 years to complete [51]. TLD1433, like many Ru(II) complexes, is inspired by the complex [Ru(bpy)3]2+, but other structures have been suggested for luminescent anticancer agents. Alternative structures include the addition of cyclometallated ligands, so-called piano stool geometry, and derivatives with appended peptides or long-chain hydrophilic groups.
3.1. Tris(bipyridine)ruthenium(II)-Inspired Complexes
Tris(bipyridine)ruthenium(II) ([Ru(bpy)3]2+)-inspired complexes were reviewed in detail at the end of 2018 and included in an account of the early development of TDL1433 by McFarland and colleagues [50]. Here, we provide a brief overview of TDL1433, focus on innovations within the past 5 years, and refer readers to McFarland’s review for seminal details [50]. TDL1433 contains functionalized aromatic chromophores with a low-lying triplet intra-ligand state, which makes them ideal for PDT. It is highly photosensitive and has long lifetimes, as well as 1O2 generation in both normoxic and hypoxic cells, despite having weak absorption within the biological window. This complex was designed with non-muscle-invasive bladder cancer in mind. This was done in a multidisciplinary approach described as “lateral”, as opposed to creating novel photosensitizers to find a suitable tumor target or retro-designing tumor specific complexes based on tumor properties. TDL1433 was part of a family of complexes tested with a range of different photophysical properties (Figure 5: TDL1433). The strategy of making premeditated incremental changes to the structure of tris NˆN Ru complexes is well established; for example, the Gasser group published two complexes with the structure [Ru(phen)2(7R,8R-dppz-)]2+, where R was either OH or OMe. Both complexes displayed intense phosphorescence, good 1O2 quantum yields, but different cellular accumulation, as well as toxicity......"